Kennedy Capital Management’s NewAmsterdam Pharma NAMS Stock Holding History

Kennedy Capital Management’s Portfolio NAMS Stock Details NAMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$14.3M	Buy	421,374 +12,882	+3%	+$425K	0.25%	132
2026 Q1	$13.1M	Buy	408,492 +235,561	+136%	+$7.67M	0.28%	131
2025 Q4	$6.07M	Buy	172,931 +26,216	+18%	+$954K	0.13%	260
2025 Q3	$4.17M	Buy	146,715 +133,040	+973%	+$3.19M	0.09%	326
2025 Q2	$248K	Buy	+13,675	New	+$249K	0.01%	556
2025 Q1	–	Sell	-7,945	Closed	-$204K	–	682
2024 Q4	$204K	Sell	7,945 -6,101	-43%	-$130K	﹤0.01%	660
2024 Q3	$233K	Buy	14,046 +2,193	+19%	+$37.9K	0.01%	670
2024 Q2	$228K	Buy	+11,853	New	+$238K	﹤0.01%	678

Other funds holding NAMS

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

DFO

Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

Kennedy Capital Management's NAMS Position: Q2 2026 in Review

Kennedy Capital Management increased its NewAmsterdam Pharma (NAMS) stake by 3.2% in Q2 2026, buying an estimated $425K and bringing the position to 421,374 shares worth $14.3M. The position accounts for 0.25% of the portfolio, ranked #132.

Kennedy Capital Management first reported a position in NAMS in Q2 2024 and has held it in 8 quarters since. 195 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

Kennedy Capital Management held 421,374 shares of NewAmsterdam Pharma worth $14.3M as of Q2 2026.
Kennedy Capital Management bought 12,882 NewAmsterdam Pharma shares in Q2 2026, an estimated $425K.
NewAmsterdam Pharma made up 0.25% of Kennedy Capital Management's portfolio in Q2 2026, its #132 holding.
Kennedy Capital Management first reported a position in NewAmsterdam Pharma in Q2 2024 and has held it in 8 quarters since.
195 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on Kennedy Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.